MedTrace Logo

Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg

NCT04544319 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-09-11

No results posted yet for this study

Summary

To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg

Conditions

  • T2DM

Interventions

DRUG

Zemiglo 50mg and Forxiga 10mg

Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD

DRUG

Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg

Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • seunghwan Lee · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2021-03-31
Completion
2021-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04544319 on ClinicalTrials.gov